FrançaisAre analysts right about Roivant Sciences (ROIV)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Roivant Sciences, we replayed every analyst price target of the past 12 months and measured the real outcome: 50% were profitable, average return +31% (62 calls). At 3 months: +9% average return (54% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| HC Wainwright & Co. | 20 | 55% | +44% |
| Cantor Fitzgerald | 9 | 22% | +22% |
| JP Morgan | 6 | 83% | +33% |
| Truist Securities | 5 | 20% | -7% |
| SVB Leerink | 5 | 80% | +75% |
Frequently asked questions
Is Roivant Sciences a buy right now?
The analyst consensus on Roivant Sciences (ROIV) is "Buy" (24 bullish, 0 bearish calls over 12 months). This is not advice: historically, 50% of their targets on this stock turned out profitable over 1 year.
What is Roivant Sciences's price target?
The median 12-month price target is $41.00 (+9% vs $37.58), ranging from $40.00 to $46.00 (5 analysts).
Are analysts accurate on Roivant Sciences?
Over 1 year, 50% of analyst targets on Roivant Sciences were profitable, for an average return of +31% (across 62 timestamped calls). This is JPI Invest's accuracy metric.
What is the Roivant Sciences stock forecast?
Analysts target a median of $41.00 within 12 months, i.e. +9% vs the current price. The most bullish targets $46.00, the most cautious $40.00.
What is the Roivant Sciences stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $41.00, +9%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (50%), and the stock's past trajectory.
Is Roivant Sciences overvalued?
Detailed valuation data for Roivant Sciences is available in the interactive analysis.
📊 See the full interactive analysis of Roivant Sciences →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.